Despite the pivotal role of IDO1 in anti‐cancer immunity and the strong pre‐clinical rationale for IDO1 inhibition as an oncological target, clinical trials have not yielded the anticipated success.27, 60, 61. The gene discussed is IDO1; the disease is cancer.